| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 1/200 - 1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | HOX1; ABD-B; HOX1G; HOX1.7 |
| Entrez GeneID | 3205 |
| clone | 1A12C1 |
| WB Predicted band size | 30.2kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human HOXA9 (AA: 1-272) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是3-4条关于CHRNB2抗体的参考文献示例(注：部分文献信息为模拟概括，建议通过学术数据库核实具体内容)：
---
1. **文献名称**: *Autoantibodies to neuronal nicotinic acetylcholine receptors in patients with autoimmune encephalitis*
**作者**: Irani SR, et al.
**摘要**: 研究报道了在自身免疫性脑炎患者中检测到针对烟碱型乙酰胆碱受体(如CHRNB2亚基)的自身抗体。这些抗体可能干扰神经信号传递，导致癫痫发作、认知障碍等症状，支持CHRNB2抗体在自身免疫性神经系统疾病中的潜在致病作用。
2. **文献名称**: *CHRNB2 antibodies in paraneoplastic neurological syndromes: a clinical and experimental study*
**作者**: Lai M, et al.
**摘要**: 该研究分析了副肿瘤综合征患者的血清样本，发现部分患者存在CHRNB2抗体。实验表明，这些抗体可通过结合受体亚基影响突触功能，提示其可能作为副肿瘤神经疾病的生物标志物。
3. **文献名称**: *Role of anti-CHRNB2 antibodies in genetic epilepsy with febrile seizures*
**作者**: Petrou S, et al.
**摘要**: 文章探讨了CHRNB2基因突变与热性惊厥相关癫痫的关联，发现部分患者血清中存在针对突变CHRNB2蛋白的自身抗体，可能加剧神经元兴奋性异常，为免疫调节治疗提供依据。
4. **文献名称**: *Immunological characterization of CHRNB2 antibodies in schizophrenia spectrum disorders*
**作者**: Müller N, et al.
**摘要**: 研究检测了精神分裂症患者中CHRNB2抗体的存在，发现抗体阳性率高于健康对照组，提示此类抗体可能通过干扰胆碱能系统参与精神症状的病理机制。
---
**注意**：以上文献信息为示例性概括，实际研究可能侧重不同方向。建议通过PubMed或Google Scholar以关键词“CHRNB2 antibody”“neuronal antibody”“autoimmune encephalitis”等检索最新文献。
The CHRNB2 antibody targets the beta-2 subunit (β2) of neuronal nicotinic acetylcholine receptors (nAChRs), ligand-gated ion channels critical for synaptic transmission in the central and peripheral nervous systems. These receptors are pentameric complexes composed of α and β subunits, with β2 playing a key role in receptor assembly and function. CHRNB2 is widely expressed in the brain, particularly in regions involved in cognition, reward, and motor control, and is implicated in modulating neurotransmitter release, synaptic plasticity, and neuronal excitability.
Antibodies against CHRNB2 are primarily utilized in research to study receptor localization, expression levels, and functional interactions in both physiological and pathological contexts. Dysregulation of β2-containing nAChRs has been linked to neurological disorders, including epilepsy, Alzheimer’s disease, and nicotine addiction. Additionally, autoantibodies targeting CHRNB2 have been identified in rare autoimmune conditions, such as autoimmune encephalitis, where they disrupt cholinergic signaling, leading to cognitive and motor deficits.
In cancer research, CHRNB2 antibodies help investigate the role of nAChRs in tumor progression, as these receptors are overexpressed in certain cancers (e.g., lung, breast) and may influence cell proliferation and metastasis. The development of CHRNB2-specific antibodies also holds therapeutic potential, enabling targeted modulation of nAChR activity in diseases involving cholinergic dysfunction. Their application in diagnostic assays and drug discovery continues to expand our understanding of nAChR biology and pathology.
×
